OBSTRUCTIVE SLEEP APNEA SYNDROME IN CHILDREN WITH TYPE II MUCOPOLYSACCHARIDOSIS (HUNTER SYNDROME)

17 children received cardiorespiratory monitoring in order to evaluate spread and dynamics of changes in the primary obstructive sleep apnea syndrome (OSAS) parameters at type II mucopolysaccharidosis. Mild OSAS [apnea/hypopnea index (AHI) – 1.5-5] was diagnosed in 4 patients (23.5%), moderate OSAS (AHI – 5-10) – in 4 patients (23.5%), severe OSAS (AHI>10) – in 2 patients (11.8%). Average AHI at Hunter syndrome was 5.3±6.9/hour. Mild OSAS (AHI – 0.8±0.3/hour) was prevalent in the group of younger children (1-3 years of age); severe OSAS was prevalent in the group of adolescents (AHI – 10.9±9.4/hour); average blood oxygen saturation (SpO₂) was 87.5±10.6%, desaturation index – 10.4±13.3/hour. In total, OSAS was observed in 58.8% of children and aggravated in direct proportion to aggravation of the disease course. Thus, cardiorespiratory monitoring is necessary to reveal children with moderate and severe OSAS course with subsequent prevention of life-threatening conditions, which may appear at this syndrome.

1. Martin R., Beck M., Eng C., Giurliani R., Harmatz P. et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008; 121: e377–e386.

2. Muenzer J., Beck M., Eng C. M. et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011; 13: 95–101.

3. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatol. 2011; 50 (Suppl. 5): v4–v12.

4. Muenzer J., Beck M., Eng C. et al. Multidisciplinary management of hunter syndrome. Pediatrics. 2009; 124 (6): 1228–1239.

5. Vashakmadze N. D., Namazova-Baranova L. S., Gevorkyan A. K., Kuzenkova L. M., Khristochevskii A. D., Vysotskaya L. M., Dadashev A. S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (3): 66–68.

6. Shih S. L., Lee Y. J., Lin S. P., Sheu C. Y., Blickman J. G. Airway changes in children with mucopolysaccharidoses. Acta Radiol. 2002; 43: 40–43.

7. Namazova-Baranova L., Gevorkyan A., Polunina T., Vashaкmadze N., Toropchina L., Gubanova S., Zelenkova I. The condition of hearing in patients with varying types of mucopolysaccharidosis (MPS). Abstracts for the Lysosomal Disease Network's WORLD Symposium Molecular Genetics and Metabolism. 108 (2013). p. 60.

8. Leboulanger N., Louis B., Vialle R. et al. Analysis of the upper airway by the acoustic reflection method in children with mucopolysaccharidosis. Pediatr. Pulmonol. 2011; 46: 587–594.

9. Kamin W. Diagnisis and management of respiratory involment in Hunter syndrome. Acta Paediatr. 2008; 97 (Suppl.): 57–60.

10. Baranov A. A., Namazova-Baranova L. S., Gevorkyan A. K., Krasnov V. M., Kuzenkova L. M., Karkashadze G. A., Vashakmadze N. D., Podkletnova T. V. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (5): 5–12.

11. Leighton S. E. J., Papsin B., Vellodi A., Dinwiddie R., Lane R. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2001; 58: 127–138.

12. Lin H. Y., Chen M. R., Lin C. C. et al. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr. Pulmonol. 2010; 45: 1205–1212.

13. Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr. 2008; 97 (Suppl.): 57–60.

14. Dempsey J. A., Veasey S. C., Morgan B. J., O’Donnell C. P. Pathophysiology of sleep apnea. Physiol. Rev. 2010; 90: 47–112.

15. Jeong H. S., Cho D. Y., Ahn K. M., Jin D. K. Complications of tracheotomy in patients with mucopolysaccharidoses type II (Hunter syndrome). Int. J. Pediatr. Otorhinolaryngol. 2006; 70: 1765–1769.

16. Ginzburg A. S., Onal E., Aronson R. M., Schild J. A., Mafee M. F., Lopata M. Successful use of nasal-CPAP for obstructive sleep apnea in Hunter syndrome with diffuse airway involvement. Chest. 1990; 97: 1496–1498.

17. Yeung A. H., Cowan M. J., Horn B., Rosbe K. W. Airway management in children with mucopolysaccharidoses. Arch. Otolaryngol. Head Neck Surg. 2009; 135: 73–79.